Tuesday, August 31, 2010   

Presenters
Pete Koval
Denosumab: RankLing with a new osteoporosis antiresorptive
Objectives:
    1. Compare and contrast the mechanism of action of denosumab with the bisphosphonates
    2. Discuss the current place in practice of denosumab in both the osteoporosis and oncology settings
    3. Describe the potential adverse effects of denosumab

Erin Allender 
 The great debate: should genetic or platelet function testing be used to individualize thienopyridine regimens?
Objectives:
1. Discuss the differential advantages and disadvantages of genetic testing versus platelet function testing to predict and assess the physiologic effect of clopidogrel on platelets
2. List the strengths and weaknesses of clinical trials exploring the use of platelet function testing to predict post-procedural ishemic events and bleeding and perioperative bleeding risk
3. Describe how the results of ongoing clinical trials may be used to individualize thienopyridine regimens

Mary Parker
Updates in antiarrhythmic pharmacotherapy
Objectives:
1. Describe the pharmacologic activity of dronedarone
2. Outline key findings in the dronedarone literature reviewed
3. Identify potential places in therapy for use of dronedarone

     Location:  Institute of Pharmacy; 109 Church St, Chapel Hill
**Parking available in lot on the corner of Franklin and Church Street. 
                  
      RSVP by August 24, 2010

**RSVP and pay for meeting registration under the "Meeting Registration" tab**